Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date17 Jan 2024 |
100 Clinical Results associated with NeoBio Co., Ltd.
0 Patents (Medical) associated with NeoBio Co., Ltd.
100 Deals associated with NeoBio Co., Ltd.
100 Translational Medicine associated with NeoBio Co., Ltd.